报告期内，公司聚焦主业，坚持产品创新、技术服务、国际化发展战略，推动各项业务持续稳定健康发 展。预计 2025 年度实现归母净利润约 5.8 亿元至 6.1 亿元，同比增长约62.55%至 70.96%。 大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公告中解释本次业绩变动的原因为： 证券之星消息，大博医疗发布业绩预告，预计2025年全年每股收益盈利:1.43元至1.5元。 ...

人民财讯1月26日电，大博医疗（002901）1月26日发布业绩预告，预计2025年归母净利润5.8亿元—6.1 亿元，同比增长62.55%—70.96%。 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 每经AI快讯，大博医疗1月26日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润5.8亿元 ~6.1亿元，同比增长62.55%~70.96%；基本每股收益1.43元~1.5元。业绩变动主要原因是，报告期内， 公司聚焦主业，坚持产品创新、技术服务、国际化发展战略，推动各项业务持续稳定健康发展。预计 2025年度实现归母净利润约5.8亿元至6.1亿元，同比增长约62.55%至70.96%。 ...

大博医疗科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 （1）以区间数进行业绩预告的 | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | 盈利：58,000 | 万元–61,000 | 万元 | 盈利：35,680.34 | 万元 | | | | 比上年同期增长：62.55%–70.96% | | | | | | 扣除非经常性损 益后的净利润 | | 盈利：45,500 | 万元–48,500 | 万元 | 盈利：28,540.35 | 万元 | | | | 比上年同期增长：59.42%–69.93% | | | | | | 基本每股收益 | | 盈利：1.43 | 元/股–1.50 | 元/股 | 盈利：0.8 ...

Core Viewpoint - Dabo Medical (002901) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the medical high-value consumables sector [2]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, an increase of 22.69% year-on-year [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a substantial growth of 77.03% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 346 million yuan, up by 63.99% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 666 million yuan, a year-on-year increase of 17.82% [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, marking a 77.49% increase year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 123 million yuan, up by 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Market Activity - As of January 23, 2026, Dabo Medical's stock closed at 50.15 yuan, with an increase of 1.48% [1]. - The trading volume was 20,400 hands, with a total transaction amount of 102 million yuan [1]. - The net outflow of main funds was 1.6977 million yuan, accounting for 1.67% of the total transaction amount, while retail investors saw a net inflow of 6.51 million yuan, representing 6.4% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, one institution has given a buy rating for Dabo Medical [3].

Core Viewpoint - The stock of Dabo Medical (002901) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][3]. Group 1: Stock Performance - As of January 22, 2026, Dabo Medical's stock closed at 49.42 yuan, down 1.06% with a turnover rate of 0.58% and a trading volume of 16,800 lots, amounting to a transaction value of 83.36 million yuan [1]. - The net outflow of main funds on January 22 was 1.92 million yuan, accounting for 2.31% of the total transaction value, while retail investors saw a net inflow of 1.26 million yuan, representing 1.51% of the total [1]. Group 2: Financial Metrics and Industry Comparison - Dabo Medical's total market capitalization is 20.461 billion yuan, significantly higher than the industry average of 11.31 billion yuan, ranking 12th out of 127 companies in the medical device sector [2]. - The company reported a net profit of 425 million yuan for the first three quarters of 2025, a year-on-year increase of 77.03%, with a gross margin of 71.23%, which is well above the industry average of 50.94% [2]. - The company's return on equity (ROE) stands at 12.83%, placing it 7th in the industry, while its price-to-earnings ratio (P/E) is 36.14, significantly lower than the industry average of 97.34 [2].

（编辑 丛可心） 证券日报网讯 1月16日，大博医疗发布公告称，公司第三届董事会第二十一次会议审议通过《关于选举 第四届董事会独立董事的议案》《关于选举公司第四届董事会非独立董事的议案》《关于提请召开2026 年第一次临时股东会的议案》等多项议案。 ...

Core Viewpoint - Dabo Medical (002901.SZ) is establishing a special fund in collaboration with Xiamen Zhongshan Hospital Foundation to promote humanitarian efforts in healthcare, with a donation of 3 million RMB [1] Group 1: Fund Establishment - The company and its subsidiary, Shiaide (Xiamen) Medical Equipment Co., Ltd., will jointly initiate the "Dabo Medical Group Special Fund" [1] - The fund aims to support the development of medical services, including infrastructure construction, medical equipment procurement, and assistance for impoverished patients [1] Group 2: Financial Commitment - The total amount pledged by the company and its subsidiary for the charitable fund is 3 million RMB [1] - According to relevant regulations, this proposal does not require approval from the shareholders' meeting [1]

Core Viewpoint - Dabo Medical (002901.SZ) aims to standardize and reduce related party transactions while leveraging the sales advantages of its affiliate, Baimaisi (Xiamen) Medical Technology Co., Ltd, to enhance the market share of its subsidiary, Shenzhen World Surgical Medical Instrument Technology Co., Ltd [1] Group 1 - Dabo Medical plans to acquire a 45.08% stake in Baimaisi (Xiamen) from shareholder He Xizhong for a consideration of 3.7645 million RMB [1]

格隆汇1月16日丨大博医疗(002901.SZ)公布，为弘扬公司"大爱无疆"的人道精神，公司及子公司施爱德 （厦门）医疗器材有限公司（简称"施爱德"）拟与厦门中山医院基金会联合发起设立"大博医疗集团专 项基金"，用于资助医疗事业的发展，包括但不限于基础设施建设，医疗设备购置，贫困病患帮扶等内 容。公司及子公司施爱德本次拟捐赠爱心基金数额为人民币300万元。根据《深圳证券交易所股票上市 规则》《公司章程》等相关规定，本议案无需提交股东会审议。 （原标题：大博医疗(002901.SZ)：拟与厦门中山医院基金会联合发起设立"大博医疗集团专项基金"） ...